CELULARITY INC
NASDAQ: CELU (Celularity Inc.)
Kemas kini terakhir: semalam, 6:18AM2.29
-0.20 (-8.03%)
| Penutupan Terdahulu | 2.49 |
| Buka | 2.51 |
| Jumlah Dagangan | 78,021 |
| Purata Dagangan (3B) | 120,715 |
| Modal Pasaran | 54,843,668 |
| Harga / Jualan (P/S) | 0.920 |
| Harga / Buku (P/B) | 5.84 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 9 May 2025 |
| Margin Keuntungan | -72.72% |
| Margin Operasi (TTM) | -124.00% |
| EPS Cair (TTM) | -100.39 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 145.50% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -60.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 399.66% |
| Nisbah Semasa (MRQ) | 0.190 |
| Aliran Tunai Operasi (OCF TTM) | -12.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -22.50 M |
| Pulangan Atas Aset (ROA TTM) | -17.45% |
| Pulangan Atas Ekuiti (ROE TTM) | -147.50% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Celularity Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 2.0 |
| Purata | -0.13 |
|
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 55.61% |
| % Dimiliki oleh Institusi | 14.89% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| C V Starr & Co Inc | 31 Mar 2025 | 764,069 |
| Biltmore Family Office, Llc | 31 Mar 2025 | 35,000 |
| Keynote Financial Services Llc | 31 Mar 2025 | 25,023 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 09 May 2025 | Pengumuman | Celularity Announces Full Year 2024 Operating and Financial Results |
| 25 Apr 2025 | Pengumuman | Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees |
| 14 Apr 2025 | Pengumuman | Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products |
| 07 Apr 2025 | Pengumuman | Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology |
| 25 Feb 2025 | Pengumuman | Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |